Efficacy of pneumococcal vaccination in adults: a meta-analysis

Huss, Anke; Scott, Pippa; Stuck, Andreas E.; Trotter, Caroline; Egger, Matthias
January 2009
CMAJ: Canadian Medical Association Journal;1/6/2009, Vol. 180 Issue 1, p48
Academic Journal
Background: Clinical trials and meta-analyses have produced conflicting results of the efficacy of unconjugated pneumococcal polysaccharide vaccine in adults. We sought to evaluate the vaccine's efficacy on clinical outcomes as well as the methodologic quality of the trials. Methods: We searched several databases and all bibliographies of reviews and meta-analyses for clinical trials that compared pneumococcal polysaccharide vaccine with a control. We examined rates of pneumonia and death, taking the methodologic quality of the trials into consideration. Results: We included 22 trials involving 101 507 participants: 11 trials reported on presumptive pneumococcal pneumonia, 19 on all-cause pneumonia and 12 on allcause mortality. The current 23-valent vaccine was used in 8 trials. The relative risk (RR) was 0.64 (95% confidence interval [CI] 0.43-0.96) for presumptive pneumococcal pneumonia and 0.73 (95% CI 0.56-0.94) for all-cause pneumonia. There was significant heterogeneity between the trials reporting on presumptive pneumonia (I2 = 74%, p < 0.001) and between those reporting on all-cause pneumonia (I2 = 90%, p < 0.001). The RR for all-cause mortality was 0.97 (95% CI 0.87-1.09), with moderate heterogeneity between trials (... = 44%, p = 0.053). Trial quality, especially regarding double blinding, explained a substantial proportion of the heterogeneity in the trials reporting on presumptive pneumonia and all-cause pneumonia. There was little evidence of vaccine protection in trials of higher methodologic quality (RR 1.20, 95% CI 0.75-1.92, for presumptive pneumonia; and 1.19, 95% CI 0.95-1.49, for all-cause pneumonia in double-blind trials; p for heterogeneity > 0.05). The results for all-cause mortality in double-blind trials were similar to those in all trials combined. There was little evidence of vaccine protection among elderly patients or adults with chronic illness in analyses of all trials (RR 1.04, 95% CI 0.78-1.38, for presumptive pneumococcal pneumonia; 0.89, 95% CI 0.69- 1.14, for all-cause pneumonia; and 1.00, 95% CI 0.87-1.14, for all-cause mortality). Interpretation: Pneumococcal vaccination does not appear to be effective in preventing pneumonia, even in populations for whom the vaccine is currently recommended.


Related Articles

  • A strategy for prevention. Kassianos, George // Pulse;6/25/2005 Supplement, Vol. 65, p6 

    Focuses on the effectiveness of pneumococcal polysaccharide vaccine (PPV) in preventing invasive pneumococcal disease in adults in Great Britain. Joint Committee on Vaccination and Immunisation's recommendation of vaccination for individuals over the age of 65; Vaccination policy in Scotland and...

  • How much has PCV reduced radiographic pneumonia? Burke, Michael G. // Contemporary Pediatrics;Mar2009, Vol. 26 Issue 3, p42 

    The article discusses research on the use of pneumococcal conjugate vaccine (PCV) to lessen incidence of radiographic pneumonia. It references a study by M. S. Rutman et al, published in a 2009 issue of "Pediatric Emergency Care." According to the study involving 889 young highly febrile...

  • Invasive Pneumococcal Disease, Comorbidities, and Polysaccharide Vaccine Use in Children Aged 5–15 Years in England and Wales. Ladhani, Shamez N.; Andrews, Nick J.; Waight, Pauline; Borrow, Ray; Slack, Mary P. E.; Miller, Elizabeth // Clinical Infectious Diseases;Feb2014, Vol. 58 Issue 4, p517 

    Comorbidity was present in 29% of 423 children aged 5–15 years with invasive pneumococcal disease (IPD), of whom 27% had received the 23-valent pneumococcal polysaccharide vaccine (PPV23). There was no association between development of PPV23-IPD and prior PPV23 receipt.Background. In the...

  • Older adults are still not receiving pneumococcal vaccine.  // Modern Medicine;Jul95, Vol. 63 Issue 7, p35 

    Reports on the low vaccination rates for pneumococcal pneumonia due to incomplete vaccination of older adults in the United States based on a survey by Mark A. Miller presented at the International Conference of the American Lung Association and American Thoracic Society on May 20-24, 1995. ...

  • Flag charts to assure vaccination against pneumococcal pneumonia.  // Geriatrics;Nov97, Vol. 52 Issue 11, p17 

    Focuses on flagging patient's chart to assure vaccination against pneuomococcal pneumonia. Recommendations of Chatrchai Watanakunakorn, director of infectious disease at Saint Elizabeth Health Center in Youngstown, Ohio about pneumococcal vaccine; Results of Watanakunakorn's study on patients...

  • Appropriateness of a Pneumococcal Conjugate Vaccine in Brazil: Potential Impact of Age and Clinical Diagnosis, with Emphasis on Meningitis. Brandileone, Maria-Cristina C.; Sgambatti de Andrade, Ana-Lucia S.; Di Fabio, José-Luis; Guerra, Maria-Luiza L.S.; Austrian, Robert // Journal of Infectious Diseases;4/15/2003, Vol. 187 Issue 8, p1206 

    Analyzes the distribution of pneumococcal serotypes in Brazil by age group and clinical diagnosis, using data obtained during 20 years of national surveillance. Indication that serotypes 1 and 5 are among the main serotypes in all age groups; Finding that the use of conjugate vaccine may be of...

  • Pneumonia vaccine saves lives.  // New York Amsterdam News;10/09/97, Vol. 88 Issue 41, p18 

    Presents information on a vaccine for pneumococcal pneumonia, an illness that claims thousands of lives annually. Comments from Daniel M. Musher, an infectious disease expert at Houston's Baylor College of Medicine and Veterans Affairs Medical Center; How the vaccine will help patients.

  • Pneumococcal Vaccine: The Evidence Mounts. LaForce, Marc // Annals of Internal Medicine;Jan86, Vol. 104 Issue 1, p110 

    Editorial. Explores the efficacy of pneumococcal pneumonia vaccine in the U.S. Results of field trials; Approach in measuring vaccine efficacy; Recommendations on the use of pneumococcal vaccine.

  • Pneumonia Vaccine--Don't Leave Home Without It. Brown, Edwin W. // Medical Update;Mar99, Vol. 22 Issue 9, p4 

    Focuses on pneumonia vaccine in the United States. Types of people eligible for the vaccine; Reasons for people's reluctance to be vaccinated.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics